Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases.

Ciancio N, Pavone M, Torrisi SE, Vancheri A, Sambataro D, Palmucci S, Vancheri C, Di Marco F, Sambataro G.

Multidiscip Respir Med. 2019 May 15;14:17. doi: 10.1186/s40248-019-0179-2. eCollection 2019. Review.

2.

Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2019 May 9;53(5). pii: 1900615. doi: 10.1183/13993003.00615-2019. Print 2019 May. No abstract available.

PMID:
31072878
3.

MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: A pilot study.

Rizzacasa B, Morini E, Mango R, Vancheri C, Budassi S, Massaro G, Maletta S, Macrini M, D'Annibale S, Romeo F, Novelli G, Amati F.

PLoS One. 2019 May 6;14(5):e0216363. doi: 10.1371/journal.pone.0216363. eCollection 2019.

4.

Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients.

Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Colaci M, Pavone M, Pignataro F, Del Papa N, Palmucci S, Vancheri C.

Respir Med. 2019 Apr;150:154-160. doi: 10.1016/j.rmed.2019.03.011. Epub 2019 Mar 25.

PMID:
30961944
5.

Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis.

Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells AU, Vasakova M, Pesci A, Klepetko W, Seeger W, Crestani B, Leidl R, Holle R, Schwarzkopf L, Guenther A.

Respir Res. 2019 Mar 1;20(1):47. doi: 10.1186/s12931-019-1010-5.

6.

Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality.

Loeh B, Brylski LT, von der Beck D, Seeger W, Krauss E, Bonniaud P, Crestani B, Vancheri C, Wells AU, Markart P, Breithecker A, Guenther A.

Chest. 2019 May;155(5):972-981. doi: 10.1016/j.chest.2019.01.019. Epub 2019 Feb 8.

PMID:
30742809
7.

The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.

Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messore B, Tomassetti S, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network).

Clin Respir J. 2019 Mar;13(3):166-173. doi: 10.1111/crj.12999.

PMID:
30675755
8.

Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series.

Sambataro G, Sambataro D, Pignataro F, Torrisi SE, Vancheri A, Pavone M, Palmucci S, Del Papa N, Vancheri C.

Respir Med Case Rep. 2018 Dec 21;26:126-130. doi: 10.1016/j.rmcr.2018.12.014. eCollection 2019.

9.

The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study.

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2019 Mar 7;53(3). pii: 1801587. doi: 10.1183/13993003.01587-2018. Print 2019 Mar.

PMID:
30578385
10.

Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.

Holtze C, Flaherty K, Kreuter M, Luppi F, Moua T, Vancheri C, Scholand MB.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180078. doi: 10.1183/16000617.0078-2018. Print 2018 Dec 31. Review.

11.

Role of imaging in progressive-fibrosing interstitial lung diseases.

Walsh SLF, Devaraj A, Enghelmayer JI, Kishi K, Silva RS, Patel N, Rossman MD, Valenzuela C, Vancheri C.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180073. doi: 10.1183/16000617.0073-2018. Print 2018 Dec 31. Review.

12.

Conditioned Media From Glial Cells Promote a Neural-Like Connexin Expression in Human Adipose-Derived Mesenchymal Stem Cells.

Lo Furno D, Mannino G, Pellitteri R, Zappalà A, Parenti R, Gili E, Vancheri C, Giuffrida R.

Front Physiol. 2018 Nov 29;9:1742. doi: 10.3389/fphys.2018.01742. eCollection 2018.

13.

Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes.

Torrisi SE, Palmucci S, Stefano A, Russo G, Torcitto AG, Falsaperla D, Gioè M, Pavone M, Vancheri A, Sambataro G, Sambataro D, Mauro LA, Grassedonio E, Basile A, Vancheri C.

Multidiscip Respir Med. 2018 Dec 1;13:43. doi: 10.1186/s40248-018-0155-2. eCollection 2018.

14.

Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study.

Wijsenbeek M, Bendstrup E, Valenzuela C, Henry MT, Moor C, Bengus M, Perjesi A, Gilberg F, Kirchgaessler KU, Vancheri C.

Adv Ther. 2019 Jan;36(1):232-243. doi: 10.1007/s12325-018-0845-3. Epub 2018 Nov 30.

15.

Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients.

Crimi C, Heffler E, Augelletti T, Campisi R, Noto A, Vancheri C, Crimi N.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 8;13:3131-3139. doi: 10.2147/COPD.S171134. eCollection 2018.

16.

Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement.

Gramegna A, Aliberti S, Confalonieri M, Corsico A, Richeldi L, Vancheri C, Blasi F.

Multidiscip Respir Med. 2018 Oct 8;13:39. doi: 10.1186/s40248-018-0153-4. eCollection 2018.

17.

Comorbidities of IPF: How do they impact on prognosis.

Torrisi SE, Vancheri A, Pavone M, Sambataro G, Palmucci S, Vancheri C.

Pulm Pharmacol Ther. 2018 Dec;53:6-11. doi: 10.1016/j.pupt.2018.09.003. Epub 2018 Sep 5. Review.

PMID:
30193867
18.

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.

Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, Maurer O, Heinemann S, Costabel U, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells A, Vasakova M, Pesci A, Sofia M, Klepetko W, Seeger W, Drakopanagiotakis F, Crestani B.

Respir Res. 2018 Jul 28;19(1):141. doi: 10.1186/s12931-018-0845-5.

19.

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.

Vancheri C, Kreuter M, Richeldi L, Quaresma M, Stowasser S, Wuyts WA.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1105-1106. doi: 10.1164/rccm.201806-1116LE. No abstract available.

PMID:
30025211
20.

Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.

Flaherty KR, Kolb M, Vancheri C, Tang W, Conoscenti CS, Richeldi L.

Eur Respir J. 2018 Aug 2;52(2). pii: 1702593. doi: 10.1183/13993003.02593-2017. Print 2018 Aug.

PMID:
29946007
21.

Neural differentiation of human adipose-derived mesenchymal stem cells induced by glial cell conditioned media.

Lo Furno D, Mannino G, Giuffrida R, Gili E, Vancheri C, Tarico MS, Perrotta RE, Pellitteri R.

J Cell Physiol. 2018 Oct;233(10):7091-7100. doi: 10.1002/jcp.26632. Epub 2018 May 8.

PMID:
29737535
22.

State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances.

Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Pavone M, Rosso R, Schisano M, Crimi C, Pignataro F, Fischer A, Del Papa N, Vancheri C.

Eur Respir Rev. 2018 May 2;27(148). pii: 170139. doi: 10.1183/16000617.0139-2017. Print 2018 Jun 30. Review.

23.

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.

Harari S, Caminati A, Poletti V, Confalonieri M, Gasparini S, Lacedonia D, Luppi F, Pesci A, Sebastiani A, Spagnolo P, Vancheri C, Balestro E, Bonifazi M, Cerri S, De Giacomi F, Della Porta R, Foschino Barbaro MP, Fui A, Pasquinelli P, Rosso R, Tomassetti S, Specchia C, Rottoli P; for the ILDINET (Interstitial Lung Diseases Italian Network).

Respiration. 2018;95(6):433-440. doi: 10.1159/000487711. Epub 2018 Mar 27.

PMID:
29587263
24.

Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting.

Ferrara R, Ientile V, Piccinni C, Pasqua A, Pecchioli S, Fontana A, Alecci U, Scoglio R, Magliozzo F, Torrisi SE, Vancheri C, Vitulo P, Fantaci G, Ferrajolo C, Cazzola M, Cricelli C, Caputi AP, Trifirò G.

NPJ Prim Care Respir Med. 2018 Mar 23;28(1):10. doi: 10.1038/s41533-018-0077-7.

25.

Validation of multidisciplinary diagnosis in IPF.

Castillo D, Walsh S, Hansell DM, Vasakova M, Cottin V, Altinisik G, Palmucci S, Sterclova M, Harari S, Richeldi L, Vancheri C, Wells AU; ERICE ILD working group.

Lancet Respir Med. 2018 Feb;6(2):88-89. doi: 10.1016/S2213-2600(18)30023-7. Review. No abstract available.

PMID:
29413085
26.

Patients with IPF and lung cancer: diagnosis and management.

Tzouvelekis A, Spagnolo P, Bonella F, Vancheri C, Tzilas V, Crestani B, Kreuter M, Bouros D.

Lancet Respir Med. 2018 Feb;6(2):86-88. doi: 10.1016/S2213-2600(17)30478-2. Epub 2017 Dec 11. Review. No abstract available.

PMID:
29241977
27.

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis.

van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM, Wapenaar M, Cottin V, Wijsenbeek MS.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701157. doi: 10.1183/13993003.01157-2017. Print 2017 Oct. No abstract available.

28.

When to start and when to stop antifibrotic therapies.

Torrisi SE, Pavone M, Vancheri A, Vancheri C.

Eur Respir Rev. 2017 Oct 3;26(145). pii: 170053. doi: 10.1183/16000617.0053-2017. Print 2017 Sep 30. Review.

29.

Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.

Maher TM, Molina-Molina M, Russell AM, Bonella F, Jouneau S, Ripamonti E, Axmann J, Vancheri C.

BMC Pulm Med. 2017 Sep 15;17(1):124. doi: 10.1186/s12890-017-0468-5.

30.

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC.

PMID:
28889759
31.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

32.

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group.

Lancet Respir Med. 2017 Jul;5(7):591-598. doi: 10.1016/S2213-2600(17)30219-9. Review.

PMID:
28664861
33.

Neutrophil-To-Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Community-Acquired Pneumonia.

Cataudella E, Giraffa CM, Di Marca S, Pulvirenti A, Alaimo S, Pisano M, Terranova V, Corriere T, Ronsisvalle ML, Di Quattro R, Stancanelli B, Giordano M, Vancheri C, Malatino L.

J Am Geriatr Soc. 2017 Aug;65(8):1796-1801. doi: 10.1111/jgs.14894. Epub 2017 Apr 13.

PMID:
28407209
34.

Nanofat 2.0: experimental evidence for a fat grafting rich in mesenchymal stem cells.

Lo Furno D, Tamburino S, Mannino G, Gili E, Lombardo G, Tarico MS, Vancheri C, Giuffrida R, Perrotta RE.

Physiol Res. 2017 Sep 22;66(4):663-671. Epub 2017 Apr 12.

35.

Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.

Wapenaar M, Patel AS, Birring SS, Domburg RTV, Bakker EW, Vindigni V, Sköld CM, Cottin V, Vancheri C, Wijsenbeek MS.

Chron Respir Dis. 2017 May;14(2):140-150. doi: 10.1177/1479972316674425. Epub 2016 Dec 26.

36.

Cough in idiopathic pulmonary fibrosis.

van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, Wijsenbeek MS.

Eur Respir Rev. 2016 Sep;25(141):278-86. doi: 10.1183/16000617.0090-2015. Review.

37.

The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma.

Scichilone N, Caponetto C, Fagone E, Benfante A, Paternò A, Heffler E, Crimi N, Vancheri C.

J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1251-1252. doi: 10.1016/j.jaip.2016.06.014. Epub 2016 Jul 13. No abstract available.

PMID:
27421901
38.

What We Know About the Pathogenesis of Idiopathic Pulmonary Fibrosis.

Puglisi S, Torrisi SE, Giuliano R, Vindigni V, Vancheri C.

Semin Respir Crit Care Med. 2016 Jun;37(3):358-67. doi: 10.1055/s-0036-1580693. Epub 2016 May 27. Review.

PMID:
27231860
39.

Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay.

Palmucci S, Torrisi SE, Caltabiano DC, Puglisi S, Lentini V, Grassedonio E, Vindigni V, Reggio E, Giuliano R, Micali G, Caltabiano R, Andreula C, Foti PV, Ettorre GC, Walsh SL, Vancheri C.

Insights Imaging. 2016 Aug;7(4):571-87. doi: 10.1007/s13244-016-0495-4. Epub 2016 May 25. Review.

40.

Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis.

Conte E, Fagone E, Gili E, Fruciano M, Iemmolo M, Pistorio MP, Impellizzeri D, Cordaro M, Cuzzocrea S, Vancheri C.

Oncotarget. 2016 Jun 7;7(23):33841-54. doi: 10.18632/oncotarget.8409.

41.

New perspectives on management of idiopathic pulmonary fibrosis.

Puglisi S, Torrisi SE, Vindigni V, Giuliano R, Palmucci S, Mulè M, Vancheri C.

Ther Adv Chronic Dis. 2016 Mar;7(2):108-20. doi: 10.1177/2040622315624276. Epub 2016 Feb 1. Review.

42.

Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment.

Russell AM, Ripamonti E, Vancheri C.

BMC Pulm Med. 2016 Jan 14;16:10. doi: 10.1186/s12890-016-0171-y.

43.

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments.

De Biasi S, Cerri S, Bianchini E, Gibellini L, Persiani E, Montanari G, Luppi F, Carbonelli CM, Zucchi L, Bocchino M, Zamparelli AS, Vancheri C, Sgalla G, Richeldi L, Cossarizza A.

BMC Med. 2015 Nov 9;13:277. doi: 10.1186/s12916-015-0515-0.

44.

Idiopathic pulmonary fibrosis and cancer: do they really look similar?

Vancheri C.

BMC Med. 2015 Sep 24;13:220. doi: 10.1186/s12916-015-0478-1.

45.

Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update.

Antoniou KM, Tomassetti S, Tsitoura E, Vancheri C.

Curr Opin Pulm Med. 2015 Nov;21(6):626-33. doi: 10.1097/MCP.0000000000000217. Review.

PMID:
26390339
46.

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?

Harari S, Humbert M, Blasi F, Collard HR, Matucci-Cerinic M, Simonneau G, Vancheri C, Wells AU, Cottin V.

Eur Respir Rev. 2015 Sep;24(137):375-7. doi: 10.1183/16000617.0051-2015. No abstract available.

47.

IPF, comorbidities and management implications.

Vancheri C, Cottin V, Kreuter M, Hilberg O.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 3;32 Suppl 1:17-23. Review.

PMID:
26237439
48.

Effects of thymosin β4 and its N-terminal fragment Ac-SDKP on TGF-β-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis.

Conte E, Iemmolo M, Fruciano M, Fagone E, Gili E, Genovese T, Esposito E, Cuzzocrea S, Vancheri C.

Expert Opin Biol Ther. 2015;15 Suppl 1:S211-21. doi: 10.1517/14712598.2015.1026804. Epub 2015 Jun 22.

PMID:
26098610
49.

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.

Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, Tomassetti S, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M.

Respir Med. 2015 Jul;109(7):904-13. doi: 10.1016/j.rmed.2015.04.010. Epub 2015 Apr 25.

50.

The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.

Grimminger F, Günther A, Vancheri C.

Eur Respir J. 2015 May;45(5):1426-33. doi: 10.1183/09031936.00149614. Epub 2015 Mar 5. Review.

Supplemental Content

Loading ...
Support Center